TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 11:00 am Eastern Time.

To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue share partnership, or through franchising TRACON’s product development platform by licensing TRACON’s clinical know-how. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Disclaimer: This content is distributed by The GlobeNewswire